Delayed trial readouts
Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.
Summary
2,453 date moves: 1,669 later and 784 earlier. The median move later is 246 days.
Date moves
| Seen | Drug | Study | Phase | Old date | New date | Move |
|---|---|---|---|---|---|---|
| 2026-11-20 | NMS-03597812 | NCT06549790Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | 2029-09-15 | 2026-09-24 | −1087 days |
| 2026-11-20 | Pembrolizumab | NCT06249048Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Phase 1/2 | 2027-05 | 2026-06-17 | −318 days |
| 2026-11-20 | Esomeprazole | NCT06561542A Phase I Study of LX22001 for Injection in Healthy Subjects | Phase 1 | 2025-11-21 | 2025-01-23 | −302 days |
| 2026-11-20 | Ferric derisomaltose | NCT05251493Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy | Phase 3 | 2026-12-31 | 2026-05-31 | −214 days |
| 2026-11-20 | Selinexor | NCT02227251Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | 2026-12 | 2026-06-02 | −182 days |
| 2026-11-20 | BI 3000202 | NCT07774325A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood | Phase 1 | 2027-02-21 | 2026-10-11 | −133 days |
| 2026-11-20 | Exemestane | NCT03125746A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors | Phase 1 | 2021-10-28 | 2021-07-21 | −99 days |
| 2026-11-20 | Xanomeline/trospium chloride | NCT07204418A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants | Phase 1 | 2026-12-03 | 2026-09-28 | −66 days |
| 2026-11-20 | Pembrolizumab | NCT03161431SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | Phase 1 | 2026-08 | 2026-07-31 | −1 day |
| 2026-11-20 | AR1001 | NCT03625622Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease | Phase 2 | 2020-12-22 | 2020-12-21 | −1 day |
| 2026-11-19 | Nivolumab | NCT05795244Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) | Phase 2 | 2029-12 | 2026-02-24 | −1376 days |
| 2026-11-19 | Pregabalin | NCT04322305Pregabalin Trial for the Treatment of Alcohol Use Disorder | Phase 2 | 2025-06-30 | 2023-07-31 | −700 days |
| 2026-11-19 | CRMA-1001 | NCT07200193A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B | Phase 1/2 | 2032-12-31 | 2031-02 | −699 days |
| 2026-11-19 | tenofovir alafenamide (Vemlidy), Emtricitabine/tenofovir disoproxil fumarate, Lenacapavir (Sunlenca), Bictegravir | NCT06544733Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed | Phase 2/3 | 2028-01 | 2026-11-03 | −424 days |
| 2026-11-19 | Cadonilimab | NCT05063916Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix | Phase 2 | 2027-08-01 | 2026-11-11 | −263 days |
| 2026-11-19 | Methylprednisolone, abrocitinib, tofacitinib | NCT06119490Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis | Phase 1 | 2026-07 | 2025-10-14 | −260 days |
| 2026-11-19 | PF-08634404, Pembrolizumab | NCT06980272SSGJ-707 in Advanced Non-Small Cell Lung Cancer | Phase 3 | 2026-07-30 | 2026-02-01 | −179 days |
| 2026-11-19 | Tremelimumab, Olaparib, Durvalumab | NCT03699449An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) | Phase 2 | 2022-09 | 2022-05-17 | −107 days |
| 2026-11-19 | Nivolumab | NCT04420975Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Phase 1 | 2027-01-31 | 2026-11-12 | −80 days |
| 2026-11-19 | tilrekimig | NCT07839884A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time | Phase 3 | 2034-05-12 | 2034-04-21 | −21 days |
| 2026-11-19 | stapokibart | NCT05728684Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease | Phase na | 2024-02-28 | 2024-02-26 | −2 days |
| 2026-11-18 | Tretinoin, Pembrolizumab | NCT06484920A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL | Phase 2 | 2027-12 | 2025-06-03 | −911 days |
| 2026-11-18 | Ipilimumab, Nivolumab, tocilizumab | NCT04940299Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | Phase 2 | 2027-12-31 | 2026-11-11 | −415 days |
| 2026-11-18 | INCB123667 | NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 3 | 2028-11-15 | 2027-10-12 | −400 days |
| 2026-11-18 | Temozolomide | NCT04910022Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Phase 1/2 | 2027-05-30 | 2026-05-06 | −389 days |
| 2026-11-18 | Gemcitabine, Atezolizumab | NCT03775265Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | Phase 3 | 2027-06-01 | 2026-07-23 | −313 days |
| 2026-11-18 | Pembrolizumab, Blinatumomab | NCT03512405Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia | Phase 1/2 | 2025-11-11 | 2025-01-31 | −284 days |
| 2026-11-18 | Entrectinib | NCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Phase 2 | 2027-06-30 | 2026-10-29 | −244 days |
| 2026-11-18 | Temozolomide | NCT06931626Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer | Phase 1 | 2026-10-30 | 2026-08-20 | −71 days |
| 2026-11-18 | ARV-806 | NCT07023731A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | Phase 1/2 | 2026-11-30 | 2026-10-30 | −31 days |
| 2026-11-18 | Depemokimab | NCT07177339eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation | Phase 3 | 2029-04-30 | 2029-04-02 | −28 days |
| 2026-11-18 | Inclisiran | NCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Phase 3 | 2027-02-11 | 2027-01-16 | −26 days |
| 2026-11-18 | Tafolecimab | NCT07473960IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | 2026-09-06 | 2026-08-26 | −11 days |
| 2026-11-18 | Felcorekibart | NCT07915791A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | 2029-03-16 | 2029-03-07 | −9 days |
| 2026-11-17 | Ramucirumab | NCT06680622Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy | Phase 2 | 2027-09 | 2026-07-09 | −419 days |
| 2026-11-17 | Dostarlimab, Niraparib | NCT04068753Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer | Phase 2 | 2026-12 | 2026-08-06 | −117 days |
| 2026-11-17 | Daraxonrasib, Nab-paclitaxel, Gemcitabine | NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 3 | 2028-06 | 2028-04 | −61 days |
| 2026-11-17 | GFH276 | NCT07198321A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | Phase 1/2 | 2027-09-22 | 2027-07-30 | −54 days |
| 2026-11-17 | Axatilimab | NCT06132256MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | 2026-09 | 2026-08-27 | −5 days |
| 2026-11-14 | Oxycodone (Xtampza ER) | NCT04659317Opioid-Free Orthopaedics | Phase 3 | 2028-12 | 2026-07-20 | −865 days |
| 2026-11-14 | Elranatamab, Lenalidomide, Daratumumab | NCT06931704Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) | Phase 2 | 2030-11-30 | 2028-11-30 | −730 days |
| 2026-11-14 | OrcaGraft (Orca-Q) | NCT06900192A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis | Phase 1 | 2029-08 | 2028-06 | −426 days |
| 2026-11-14 | pemetrexed, Adebrelimab, Nab-paclitaxel | NCT05794477A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | Phase 1/2 | 2025-07-01 | 2024-08-20 | −315 days |
| 2026-11-14 | metformin | NCT04931017Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer | Phase 2 | 2026-12-31 | 2026-07-09 | −175 days |
| 2026-11-14 | Vosoritide | NCT06668805A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase 2 | 2027-03 | 2026-09-16 | −166 days |
| 2026-11-14 | BGM0504 | NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Phase 3 | 2026-11-14 | 2026-08-13 | −93 days |
| 2026-11-14 | BGM0504, Semaglutide (Ozempic) | NCT06716216A Study of BGM0504 in Participants With Type 2 Diabetes | Phase 3 | 2026-11-14 | 2026-08-25 | −81 days |
| 2026-11-14 | maralixibat | NCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | 2026-10 | 2026-07-29 | −64 days |
| 2026-11-14 | Bempedoic acid | NCT06780410A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid | Phase 3 | 2025-10 | 2025-08-05 | −57 days |
| 2026-11-14 | Benralizumab | NCT04565483Predictive Signature of Benralizumab Response | Phase 4 | 2026-10 | 2026-08-19 | −43 days |
| 2026-11-14 | Esketamine | NCT05212571Long-term Pain Modulation by Intravenous Esketamine in CRPS | Phase na | 2026-10-01 | 2026-08-20 | −42 days |
| 2026-11-13 | Ibrutinib | NCT02787369ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | Phase 1 | 2026-04 | 2019-06 | −2496 days |
| 2026-11-13 | Ifebemtinib, Furmonertinib | NCT05994131IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | Phase 1/2 | 2026-07-31 | 2025-09-20 | −314 days |
| 2026-11-13 | Naloxone (Narcan) | NCT03616236Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment | Phase 3 | 2026-08-31 | 2026-01-30 | −213 days |
| 2026-11-13 | Rituximab | NCT06040320Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) | Phase 1/2 | 2027-05-31 | 2026-11-06 | −206 days |
| 2026-11-13 | Pelcitoclax, Osimertinib | NCT04001777A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients | Phase 1 | 2025-12 | 2025-05-27 | −188 days |
| 2026-11-13 | BI 3000202 | NCT07486102A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems | Phase 1 | 2027-02-26 | 2026-10-30 | −119 days |
| 2026-11-13 | Suzetrigine | NCT07538570Evaluation of Pain Treatment After Total Knee Arthroplasty | Phase 4 | 2027-01-30 | 2026-10-12 | −110 days |
| 2026-11-13 | Vosoritide | NCT06455059Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia | Phase 3 | 2026-08-01 | 2026-04-23 | −100 days |
| 2026-11-13 | tocilizumab, Iberdomide, Obinutuzumab | NCT05169515A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | Phase 1 | 2029-08-05 | 2029-04-30 | −97 days |
| 2026-11-13 | Bofanglutide | NCT07144098Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function | Phase 1 | 2026-07-12 | 2026-04-07 | −96 days |
| 2026-11-13 | Erfonrilimab, Ifebemtinib, Nab-paclitaxel, Gemcitabine | NCT05827796IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer | Phase 1/2 | 2025-12-31 | 2025-10-11 | −81 days |
| 2026-11-13 | tulisokibart | NCT07133633A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | Phase 2 | 2027-06-15 | 2027-03-29 | −78 days |
| 2026-11-13 | Semaglutide (Wegovy), survodutide | NCT06745284A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity | Phase 1 | 2027-01-08 | 2026-11-01 | −68 days |
| 2026-11-13 | Esketamine | NCT07625826The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Open Thyroid Surgery | Phase na | 2027-05 | 2027-03 | −61 days |
| 2026-11-13 | barzolvolimab | NCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Phase 3 | 2026-10 | 2026-08-04 | −58 days |
| 2026-11-13 | barzolvolimab | NCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Phase 3 | 2026-10 | 2026-08-12 | −50 days |
| 2026-11-13 | Bofanglutide | NCT06728124A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects | Phase 3 | 2026-05 | 2026-03-26 | −36 days |
| 2026-11-13 | MT-201 | NCT07219368A First-in-Human Single and Multiple Ascending Dose Study of MT-201 | Phase 1 | 2026-11-24 | 2026-10-20 | −35 days |
| 2026-11-13 | Ifebemtinib, Tislelizumab | NCT06030258IN10018 Combination Therapy in Treatment-naïve ES-SCLC | Phase 1/2 | 2025-12-24 | 2025-11-20 | −34 days |
| 2026-11-13 | Ifebemtinib | NCT05551507IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer | Phase 1/2 | 2026-05-31 | 2026-05-11 | −20 days |
| 2026-11-13 | precemtabart tocentecan | NCT06806046Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors | Phase 1 | 2026-09-30 | 2026-09-23 | −7 days |
| 2026-11-13 | Dexamethasone, Elranatamab, Elotuzumab, Lenalidomide, Bortezomib, Pomalidomide, Carfilzomib | NCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | 2026-08-30 | 2026-08-26 | −4 days |
| 2026-11-13 | setmelanotide | NCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | Phase 3 | 2025-12-22 | 2025-12-19 | −3 days |
| 2026-11-13 | Pegcetacoplan, BI 771716 | NCT06722157A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Phase 2 | 2026-10-28 | 2026-10-26 | −2 days |
| 2026-11-11 | Luxdegalutamide | NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | 2032-03-15 | 2026-12-03 | −1929 days |
| 2026-11-11 | aldesleukin | NCT04643574NeoTIL in Advanced Solid Tumors | Phase 1 | 2027-11 | 2023-10-24 | −1469 days |
| 2026-11-11 | elasomeran | NCT04894435Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity | Phase 2 | 2024-11-15 | 2022-07-25 | −844 days |
| 2026-11-11 | Pelacarsen | NCT05900141An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 | 2028-08-24 | 2026-10-15 | −679 days |
| 2026-11-11 | Dexamethasone | NCT07330999Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults | Phase na | 2027-08-31 | 2026-05-20 | −468 days |
| 2026-11-11 | Bofanglutide | NCT07292441Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss | Phase 3 | 2027-09 | 2026-09-22 | −344 days |
| 2026-11-11 | Vebreltinib | NCT07549061Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC | Phase 2 | 2028-05-30 | 2027-09-01 | −272 days |
| 2026-11-11 | Ulonivirine | NCT07595263A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019) | Phase 1 | 2027-01-15 | 2026-09-29 | −108 days |
| 2026-11-11 | Nab-paclitaxel, Bevacizumab | NCT05075993Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | Phase 1 | 2027-02-02 | 2026-11-03 | −91 days |
| 2026-11-11 | HiCM-188 (allogeneic iPSC-cardiomyocytes) | NCT07646210HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery | Phase 1/2 | 2028-05 | 2028-02 | −90 days |
| 2026-11-11 | Bofanglutide, Semaglutide (Ozempic) | NCT06778967A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | Phase 3 | 2026-12-11 | 2026-09-18 | −84 days |
| 2026-11-11 | Tirzepatide (Zepbound) | NCT06162715GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial | Phase 2/3 | 2027-01-01 | 2026-10-10 | −83 days |
| 2026-11-11 | Rosuvastatin, Bofanglutide | NCT07128888Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection | Phase 1 | 2026-07-05 | 2026-04-13 | −83 days |
| 2026-11-11 | Rifaximin (Xifaxan) | NCT05677282Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct | Phase 4 | 2025-09 | 2025-06-29 | −64 days |
| 2026-11-11 | Ranibizumab, Bevacizumab | NCT06952452Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) | Phase 3 | 2026-07 | 2026-05-28 | −34 days |
| 2026-11-11 | retatrutide | NCT07232719A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | 2027-07 | 2027-06 | −30 days |
| 2026-11-11 | linaclotide | NCT06692673Linaclotide for Colonoscopy Bowel Prep | Phase 1/2 | 2026-04-30 | 2026-04-07 | −23 days |
| 2026-11-11 | Aflibercept | NCT06683742A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | Phase 3 | 2026-10 | 2026-09-09 | −22 days |
| 2026-11-11 | Cabotegravir/rilpivirine (Cabenuva) | NCT07650916A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed | Phase 3 | 2029-09-04 | 2029-08-13 | −22 days |
| 2026-11-11 | remibrutinib | NCT07855276A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS | Phase 1 | 2027-12-21 | 2027-11-29 | −22 days |
| 2026-11-11 | AMG 691 | NCT07745907A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers | Phase 1 | 2027-03-31 | 2027-03-17 | −14 days |
| 2026-11-11 | Ibrutinib | NCT03479268Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | Phase 1 | 2026-11-05 | 2026-10-28 | −8 days |
| 2026-11-11 | Bofanglutide | NCT06777238A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise | Phase 3 | 2026-08-07 | 2026-07-30 | −8 days |
| 2026-11-11 | VCT220 | NCT07340320A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | Phase 2 | 2027-04-16 | 2027-04-08 | −8 days |
| 2026-11-11 | metreleptin | NCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL | Phase 3 | 2026-07-21 | 2026-07-14 | −7 days |
| 2026-11-11 | Naloxone (Narcan) | NCT07459166A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade | Phase 2 | 2026-07-22 | 2026-07-15 | −7 days |
| 2026-11-11 | Modafinil | NCT07830056Modafinil to Optimize the Performance of Cold-Stressed Sleep-Deprived Personnel | Phase 4 | 2026-10 | 2026-09-24 | −7 days |
| 2026-11-11 | rilzabrutinib | NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | Phase 3 | 2026-11-30 | 2026-11-25 | −5 days |
| 2026-11-11 | lebrikizumab | NCT01987492A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma | Phase 2 | 2016-12-20 | 2016-12-19 | −1 day |
| 2026-11-10 | Ocrevus Zunovo, Ocrelizumab | NCT07667322A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis | Phase 1 | 2028-02-15 | 2026-09-01 | −532 days |
| 2026-11-10 | tocilizumab, Obinutuzumab | NCT04077723A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 1/2 | 2027-03-31 | 2026-12-28 | −93 days |
| 2026-11-10 | Niraparib | NCT04170153Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) | Phase 1 | 2026-11-30 | 2026-10-14 | −47 days |
| 2026-11-10 | ABBV-295 | NCT07514260A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity. | Phase 1 | 2027-01 | 2026-12 | −31 days |
| 2026-11-10 | Dostarlimab, Pembrolizumab | NCT05565378A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | Phase 2 | 2026-11-09 | 2026-10-26 | −14 days |
| 2026-11-10 | remibrutinib | NCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS | Phase 3 | 2031-10-29 | 2031-10-15 | −14 days |
| 2026-11-10 | Ruxolitinib (Opzelura) | NCT06958211Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | Phase 3 | 2026-10-09 | 2026-10-01 | −8 days |
| 2026-11-10 | Bevacizumab, Atezolizumab | NCT05992220Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion | Phase 2 | 2026-03 | 2026-02-25 | −4 days |
| 2026-11-10 | tralokinumab | NCT06311682A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis | Phase 3 | 2026-10-20 | 2026-10-16 | −4 days |
| 2026-11-10 | Venetoclax | NCT06524375A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period | Phase 2 | 2026-10-31 | 2026-10-28 | −3 days |
| 2026-11-10 | Cabotegravir/rilpivirine (Cabenuva) | NCT06786520A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | Phase 1 | 2027-03-09 | 2027-03-08 | −1 day |
| 2026-11-08 | onabotulinumtoxinA | NCT07577310False Vocal Fold vs EMG Guided Botox for Vocal Tremor | Phase na | 2030-07 | 2028-07 | −730 days |
| 2026-11-08 | Dexamethasone | NCT07180940Comparison of Perineural Dexamethasone Versus Dexmedetomidine as Adjuvants to Erector Spinae Plane Block in Lumbar Spine Surgery | Phase 4 | 2026-09-30 | 2025-12-30 | −274 days |
| 2026-11-08 | Avrukibart | NCT07290569Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis | Phase 2 | 2027-06 | 2026-10-21 | −223 days |
| 2026-11-08 | Carfilzomib | NCT05017545Carfilzomib and Belatacept for Desensitization | Phase 1/2 | 2027-02-28 | 2026-08-05 | −207 days |
| 2026-11-08 | Rituximab, Obinutuzumab | NCT05786768Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome | Phase 2/3 | 2027-10-18 | 2027-06-30 | −110 days |
| 2026-11-08 | enicepatide | NCT07626515A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants | Phase 1 | 2027-05-14 | 2027-04-08 | −36 days |
| 2026-11-07 | Olaparib | NCT05932862A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | 2029-01-03 | 2027-04-30 | −614 days |
| 2026-11-07 | Dapagliflozin | NCT07323524Dapagliflozin in Active Lupus Nephritis | Phase 4 | 2029-07 | 2028-07-01 | −365 days |
| 2026-11-07 | Trontinemab | NCT07717411A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | Phase 3 | 2032-09-03 | 2032-07-30 | −35 days |
| 2026-11-07 | Cemdisiran, Pozelimab, Eculizumab, Ravulizumab | NCT05133531A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment | Phase 3 | 2026-10-12 | 2026-09-28 | −14 days |
| 2026-11-07 | GSK3862995 | NCT06154837A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease | Phase 1 | 2026-12-17 | 2026-12-16 | −1 day |
| 2026-11-06 | Sacituzumab Tirumotecan | NCT06637423A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | Phase 1/2 | 2029-03-14 | 2026-09-30 | −896 days |
| 2026-11-06 | Quetiapine (Seroquel), Clozapine, valproate, Esketamine | NCT05603104Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | Phase 3 | 2028-06-30 | 2026-06-24 | −737 days |
| 2026-11-06 | Capecitabine | NCT04703101Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | Phase 1 | 2026-10-01 | 2025-07-03 | −455 days |
| 2026-11-06 | Fulvestrant, IDE574 | NCT07540572A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | Phase 1 | 2030-03-30 | 2029-12-31 | −89 days |
| 2026-11-06 | Gabapentin | NCT05443555Gabapentin to Reduce Alcohol and Improve Viral Load Suppression | Phase 2 | 2026-10 | 2026-09-24 | −7 days |
| 2026-11-06 | Efimosfermin alfa | NCT06920043A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH | Phase 2 | 2028-07-10 | 2028-07-03 | −7 days |
| 2026-11-06 | Chiglitazar, metformin | NCT07511010Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets | Phase 1 | 2026-10-26 | 2026-10-22 | −4 days |
| 2026-11-05 | Zoledronic acid, Capecitabine | NCT03073785Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer | Phase 2 | 2027-12 | 2023-12-12 | −1450 days |
| 2026-11-05 | Avutometinib/defactinib (Avmapki Fakzynja Co-Pack) | NCT06104488A Study of Avutometinib for People With Solid Tumor Cancers | Phase 1 | 2029-10-20 | 2026-11-03 | −1082 days |
| 2026-11-05 | zasocitinib | NCT07244263A Study of Zasocitinib in Adults With Hidradenitis Suppurativa | Phase 2 | 2028-02-22 | 2027-02-05 | −382 days |
| 2026-11-05 | Capecitabine | NCT05065957Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | Phase 2/3 | 2026-07 | 2025-07-31 | −335 days |
| 2026-11-05 | Beclomethasone dipropionate/formoterol fumarate | NCT06515444Experimental Evaluation of a Program to Foster Socioemotional Competence of Children in Third Grade and Their Teachers | Phase na | 2026-12-20 | 2026-08-01 | −141 days |
| 2026-11-05 | HS-20118 | NCT06846710Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118 | Phase 1 | 2026-10-30 | 2026-07-14 | −108 days |
| 2026-11-05 | Dexamethasone | NCT07386600Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA | Phase na | 2027-01-01 | 2026-09-30 | −93 days |
| 2026-11-05 | Pembrolizumab, Nab-paclitaxel, Capecitabine, Gemcitabine, Olaparib | NCT04753879Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | Phase 2 | 2026-07-01 | 2026-05-07 | −55 days |
| 2026-11-05 | Pembrolizumab | NCT05296512Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer | Phase 2 | 2026-09-23 | 2026-09-08 | −15 days |
| 2026-11-05 | Pembrolizumab | NCT06308913Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma | Phase 1 | 2026-10 | 2026-09-16 | −15 days |
| 2026-11-05 | fluticasone propionate | NCT06664619A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | 2026-11-02 | 2026-10-26 | −7 days |
| 2026-11-04 | Gemcitabine, Fianlimab, Cemiplimab | NCT06571708Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT) | Phase 2 | 2028-12 | 2026-01-05 | −1061 days |
| 2026-11-04 | jaktinib | NCT05526222A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis | Phase 3 | 2026-06 | 2025-08-05 | −300 days |
| 2026-11-04 | Pembrolizumab | NCT06005818Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) | Phase 2 | 2027-07 | 2026-10-01 | −273 days |
| 2026-11-04 | zasocitinib | NCT07108283A Study of Zasocitinib in Adults With Nonsegmental Vitiligo | Phase 2 | 2027-10-12 | 2027-03-26 | −200 days |
| 2026-11-04 | Erfonrilimab, Regorafenib | NCT05985109KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer | Phase 2 | 2026-12-31 | 2026-09-30 | −92 days |
| 2026-11-04 | Tobevibart (VIR-3434) | NCT06903338A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Phase 3 | 2026-12-31 | 2026-09-30 | −92 days |
| 2026-11-04 | Methotrexate | NCT04579848Methotrexate in Erosive Inflammatory Hand Osteoarthritis | Phase 4 | 2026-12 | 2026-09-02 | −90 days |
| 2026-11-04 | Teclistamab | NCT06425991A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | 2025-06-03 | 2025-04-21 | −43 days |
| 2026-11-04 | fluticasone propionate | NCT07597473Dymista in Chinese Adolescents | Phase 4 | 2026-10 | 2026-09-19 | −12 days |
| 2026-11-04 | Setidegrasib | NCT07773129A Study to Learn How ASP3082 is Processed in Healthy Men | Phase 1 | 2026-10-31 | 2026-10-20 | −11 days |
| 2026-11-04 | AZD4144 | NCT07685600Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants | Phase 1 | 2026-10-28 | 2026-10-22 | −6 days |
| 2026-11-04 | Axitinib, Pembrolizumab | NCT05805501A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | Phase 2 | 2026-10-08 | 2026-10-05 | −3 days |
| 2026-11-04 | JNJ-89853413 | NCT06618001A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | Phase 1 | 2026-09-02 | 2026-09-01 | −1 day |
| 2026-11-03 | Docetaxel, Gemcitabine, Eribulin mesylate, Sacituzumab Govitecan | NCT04579224Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Phase 3 | 2030-08-15 | 2026-03-05 | −1624 days |
| 2026-11-03 | adalimumab | NCT02706704Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis | Phase 2 | 2025-12 | 2022-01 | −1430 days |
| 2026-11-03 | Entrectinib, Alectinib, Durvalumab | NCT05170204A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | 2030-06-16 | 2027-01-19 | −1244 days |
| 2026-11-03 | Dexamethasone, Pomalidomide, Ixazomib | NCT02542657Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma | Phase 1/2 | 2025-08 | 2022-12-07 | −968 days |
| 2026-11-03 | Obinutuzumab beta (Bejescin) | NCT05796206A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus | Phase 2 | 2026-02 | 2024-11-21 | −437 days |
| 2026-11-03 | Lanifibranor | NCT04849728A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | 2027-09-30 | 2026-09-29 | −366 days |
| 2026-11-03 | fingolimod (Gilenya) | NCT04480853Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis | Phase 4 | 2027-09-30 | 2026-10-15 | −350 days |
| 2026-11-03 | Axitinib, Pembrolizumab | NCT05363631Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | Phase 1/2 | 2026-12-31 | 2026-06-23 | −191 days |
| 2026-11-03 | Nivolumab | NCT04652960Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome | Phase 1 | 2026-12-03 | 2026-07-22 | −134 days |
| 2026-11-03 | Nogapendekin alfa inbakicept (Anktiva) | NCT04898543QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 1 | 2026-05-31 | 2026-02-02 | −118 days |
| 2026-11-03 | Moponetug | NCT06268886Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | Phase 2 | 2027-03-18 | 2026-12-17 | −91 days |
| 2026-11-03 | Dexamethasone | NCT05132920Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage | Phase 3 | 2024-12 | 2024-09-09 | −83 days |
| 2026-11-03 | onabotulinumtoxinA | NCT07756580A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines | Phase 1 | 2027-03 | 2027-02 | −28 days |
| 2026-11-03 | Ramucirumab, Pembrolizumab | NCT04040361Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) | Phase 2 | 2022-04-30 | 2022-04-20 | −10 days |
| 2026-11-03 | Pembrolizumab, Nab-paclitaxel | NCT05852691A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | Phase 2 | 2026-10-19 | 2026-10-15 | −4 days |
| 2026-11-01 | Toripalimab | NCT06648200Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer | Phase 2 | 2030-09-01 | 2026-08-29 | −1464 days |
| 2026-11-01 | Nab-paclitaxel | NCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | Phase 2/3 | 2029-01-15 | 2027-12-01 | −411 days |
| 2026-11-01 | Nivolumab | NCT05601752ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) | Phase 2 | 2026-08-12 | 2025-09-30 | −316 days |
| 2026-11-01 | Pembrolizumab, Olaparib | NCT05093231Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | Phase 2 | 2027-07-31 | 2026-11-30 | −243 days |
| 2026-11-01 | Oxycodone (Xtampza ER) | NCT04676802Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone | Phase 4 | 2027-02 | 2026-06-18 | −228 days |
| 2026-11-01 | Pembrolizumab | NCT03371979Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | Phase 1/2 | 2021-01-01 | 2020-06-11 | −204 days |
| 2026-11-01 | Cabozantinib | NCT04876456A Phase II Trial of Cabozantinib With Patients With Refractory GCTs | Phase 2 | 2027-01 | 2026-07-31 | −154 days |
| 2026-11-01 | metformin | NCT05781711Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease | Phase 2 | 2025-01-20 | 2024-08-20 | −153 days |
| 2026-11-01 | RAY1225 | NCT06254274A Study of RAY1225 in Participants With Type 2 Diabetes | Phase 2 | 2025-12-20 | 2025-07-20 | −153 days |
| 2026-11-01 | N-acetylcysteine | NCT07803952N-Acetylcysteine in the Management of Spontaneous Bacterial Peritonitis | Phase 1/2 | 2027-09-01 | 2027-06-01 | −92 days |
| 2026-11-01 | Docetaxel, Gemcitabine, Risvutatug rezetecan | NCT06935409Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure | Phase 3 | 2026-08-31 | 2026-06-17 | −75 days |
| 2026-11-01 | Pembrolizumab | NCT07267338Pembrolizumab + MRGOO3 as Neoadjuvant in NPC | Phase 2 | 2027-12 | 2027-10 | −61 days |
| 2026-11-01 | Risvutatug rezetecan | NCT06498479ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | 2026-09-30 | 2026-08-20 | −41 days |
| 2026-11-01 | Epinephrine | NCT07724418Split Face Study of the Duration of Local Anesthetics - Fifth Arm | Phase 4 | 2027-06-30 | 2027-05-30 | −31 days |
| 2026-11-01 | Brentuximab Vedotin, Nivolumab | NCT03712202Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | Phase 2 | 2024-12-23 | 2024-11-30 | −23 days |
| 2026-11-01 | Docetaxel | NCT07711002Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) | Phase 3 | 2031-06-17 | 2031-05-30 | −18 days |
| 2026-11-01 | pemetrexed, Tislelizumab, Nab-paclitaxel | NCT05635708A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | Phase 2 | 2025-12-31 | 2025-12-19 | −12 days |
| 2026-10-31 | tenofovir alafenamide (Vemlidy), Dolutegravir, Raltegravir | NCT06337032A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments | Phase 4 | 2034-03 | 2027-06 | −2465 days |
| 2026-10-31 | Belinostat, Temozolomide | NCT02137759MRSI to Predict Response to RT/TMZ ± Belinostat in GBM | Phase 2 | 2023-08-15 | 2019-03-25 | −1604 days |
| 2026-10-31 | Vericiguat | NCT05714085Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | 2032-04-15 | 2029-08-20 | −969 days |
| 2026-10-31 | CLN-978 | NCT05879744A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1 | 2026-11 | 2024-06-01 | −883 days |
| 2026-10-31 | Trastuzumab Deruxtecan | NCT07022483A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting | Phase 3 | 2032-03-23 | 2030-02-26 | −756 days |
| 2026-10-31 | lunsekimig | NCT06914908Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study | Phase 2 | 2031-01-29 | 2029-02-22 | −706 days |
| 2026-10-31 | Botensilimab, Balstilimab | NCT05529316A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | Phase 2 | 2028-02 | 2026-04-27 | −645 days |
| 2026-10-31 | Tadalafil | NCT05195775Tadalafil as Adjuvant Therapy for DMD | Phase 2/3 | 2025-09-05 | 2024-04-16 | −507 days |
| 2026-10-31 | metformin | NCT05553704Metformin in Patients With Ulcerative Colitis Treated With Mesalamine | Phase 2 | 2025-03-01 | 2023-12-01 | −456 days |
| 2026-10-31 | Esketamine, Pregabalin | NCT07230171The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia | Phase na | 2027-06-30 | 2026-06-14 | −381 days |
| 2026-10-31 | Dapagliflozin | NCT05792540Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders | Phase 2 | 2024-11-20 | 2023-12-20 | −336 days |
| 2026-10-31 | Methylprednisolone | NCT04163536Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU | Phase 3 | 2025-10-25 | 2024-11-24 | −335 days |
| 2026-10-31 | Gemcitabine | NCT05701332Effect of Intravesical B.C.G and Gemcitabine on Semen Analysis and Testicular Volume in NMIBC | Phase 4 | 2025-12-01 | 2025-01-18 | −317 days |
| 2026-10-31 | tocilizumab, Methotrexate | NCT03892785MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial | Phase 3 | 2027-01 | 2026-03-27 | −280 days |
| 2026-10-31 | aldesleukin | NCT04055623T-regulatory Cells in ALS | Phase 2 | 2022-05-31 | 2021-08-31 | −273 days |
| 2026-10-31 | Denifanstat | NCT05743621Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | 2027-01-25 | 2026-05-12 | −258 days |
| 2026-10-31 | Bevacizumab, Atezolizumab | NCT03526432Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | Phase 2 | 2026-08-31 | 2025-12-19 | −255 days |
| 2026-10-31 | Verteporfin | NCT04590664Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | Phase 1/2 | 2025-08-15 | 2025-02-13 | −183 days |
| 2026-10-31 | Dapagliflozin | NCT07310433Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer | Phase 2 | 2029-10-30 | 2029-04-30 | −183 days |
| 2026-10-31 | Capecitabine, Temozolomide | NCT05247905Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial | Phase 2 | 2028-03-31 | 2027-10-01 | −182 days |
| 2026-10-31 | remibrutinib | NCT07855276A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS | Phase 1 | 2028-06-19 | 2027-12-21 | −181 days |
| 2026-10-31 | Selinexor | NCT03147885Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | Phase 1/2 | 2027-12 | 2027-06-25 | −159 days |
| 2026-10-31 | Budigalimab | NCT06487559A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) | Phase 1 | 2027-02 | 2026-09-18 | −136 days |
| 2026-10-31 | Avelumab, Cemiplimab, Nivolumab, Atezolizumab, Durvalumab | NCT06302426Trial of INI-4001 in Patients With Advanced Solid Tumours | Phase 1 | 2026-10-30 | 2026-06-19 | −133 days |
| 2026-10-31 | Nintedanib (Ofev) | NCT03805477Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation | Phase 2 | 2026-12 | 2026-07-29 | −125 days |
| 2026-10-31 | Ruxolitinib (Opzelura) | NCT03954236Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease | Phase 2 | 2027-02-06 | 2026-10-12 | −117 days |
| 2026-10-31 | Quemliclustat | NCT05329766A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | Phase 2 | 2027-01 | 2026-09-07 | −116 days |
| 2026-10-31 | Docetaxel, Gemcitabine | NCT05644041Intravesical Gem/Doce in Patients With NMIBC | Phase 2 | 2027-01-31 | 2026-10-19 | −104 days |
| 2026-10-31 | Cadonilimab | NCT06508606AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | 2026-11-01 | 2026-08-01 | −92 days |
| 2026-10-31 | Methotrexate | NCT05573555TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | Phase 1/2 | 2026-12-30 | 2026-10-06 | −85 days |
| 2026-10-31 | Sacituzumab Tirumotecan | NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Phase 3 | 2027-01-04 | 2026-10-19 | −77 days |
| 2026-10-31 | Pomalidomide | NCT07532525Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma | Phase 1 | 2027-10 | 2027-08 | −61 days |
| 2026-10-31 | Rademikibart | NCT06488755SIM0718 Treatment of Asthma Clinical Study | Phase 3 | 2027-02-28 | 2026-12-31 | −59 days |
| 2026-10-31 | Binimetinib | NCT05564403Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | Phase 2 | 2026-10-01 | 2026-08-08 | −54 days |
| 2026-10-31 | Ranibizumab | NCT06957080A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Phase 2/3 | 2027-03-01 | 2027-01-11 | −49 days |
| 2026-10-31 | Bevacizumab, Atezolizumab | NCT04857684SBRT + Atezolizumab + Bevacizumab in Resectable HCC | Phase 1 | 2026-04-29 | 2026-03-13 | −47 days |
| 2026-10-31 | baricitinib | NCT06240351A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA) | Phase 4 | 2026-10-31 | 2026-09-16 | −45 days |
| 2026-10-31 | Gemcitabine, Atezolizumab | NCT04630730Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | Phase 2 | 2026-06 | 2026-04-26 | −36 days |
| 2026-10-31 | Gemcitabine, Obinutuzumab | NCT07711483GLORY: Glofit-GemOx With Liso-Cel For Lymphoma | Phase 2 | 2028-10-01 | 2028-09-15 | −16 days |
| 2026-10-31 | LN-145 | NCT06566092Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | Phase 1 | 2026-07 | 2026-06-19 | −12 days |
| 2026-10-31 | neflamapimod | NCT06987643A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke | Phase 2 | 2026-09-30 | 2026-09-23 | −7 days |
| 2026-10-31 | Cemiplimab | NCT05259709A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab | Phase 1 | 2027-05-05 | 2027-04-29 | −6 days |
| 2026-10-31 | VLS-01 | NCT06524830A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Phase 2 | 2026-08-01 | 2026-07-30 | −2 days |
| 2026-10-30 | ALTB-268 | NCT07350577Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants | Phase 1 | 2026-09-26 | 2026-04-06 | −173 days |
| 2026-10-30 | Ligufalimab | NCT06508606AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | 2026-11-01 | 2026-08-01 | −92 days |
| 2026-10-30 | Docetaxel, Zanidatamab, Pertuzumab | NCT07102381A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | 2028-01-01 | 2027-12-29 | −3 days |
| 2026-10-29 | SCD-101 | NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101 | Phase 2 | 2030-02-04 | 2026-06-04 | −1341 days |
| 2026-10-29 | Durvalumab | NCT03999710Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer | Phase 2 | 2027-07 | 2026-10-20 | −254 days |
| 2026-10-29 | AC-101 | NCT07083193A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis | Phase 1/2 | 2026-09-30 | 2026-04-20 | −163 days |
| 2026-10-29 | Ticagrelor | NCT05681702Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI | Phase 4 | 2026-12-31 | 2026-08-05 | −148 days |
| 2026-10-29 | tofacitinib | NCT06393972The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis | Phase 2 | 2025-11-30 | 2025-07-11 | −142 days |
| 2026-10-29 | Bortezomib | NCT04268199A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment | Phase 2 | 2026-12 | 2026-08-31 | −92 days |
| 2026-10-29 | metformin | NCT04407650Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus | Phase 4 | 2024-12-31 | 2024-10-03 | −89 days |
| 2026-10-29 | Palbociclib, Camizestrant, Ribociclib, Abemaciclib | NCT06188520A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | Phase 1/2 | 2027-08-04 | 2027-06-30 | −35 days |
| 2026-10-29 | Sevabertinib, metformin | NCT07753252Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body | Phase 1 | 2026-10-22 | 2026-10-06 | −16 days |
| 2026-10-29 | Naloxone (Narcan) | NCT07314346Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone | Phase 1 | 2026-08 | 2026-07-23 | −9 days |
| 2026-10-28 | dupilumab | NCT07330934A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis | Phase 2 | 2027-06-30 | 2026-08-18 | −316 days |
| 2026-10-28 | Tarlatamab | NCT07803848Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status | Phase 2 | 2027-12-31 | 2027-07-29 | −155 days |
| 2026-10-28 | Vepdegestrant, Ribociclib | NCT05573555TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | Phase 1/2 | 2026-12-30 | 2026-10-06 | −85 days |
| 2026-10-28 | Iptacopan | NCT05230537A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration | Phase 2 | 2026-09-30 | 2026-08-19 | −42 days |
| 2026-10-28 | elasomeran | NCT07863635A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | Phase 4 | 2027-01-09 | 2026-12-11 | −29 days |
| 2026-10-28 | faricimab | NCT06795048A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration | Phase 4 | 2026-10-20 | 2026-10-16 | −4 days |
| 2026-10-27 | Empagliflozin, Liraglutide (Victoza) | NCT04535960Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial | Phase 2 | 2023-10 | 2021-03-16 | −929 days |
| 2026-10-27 | Patritumab Deruxtecan | NCT03260491U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | Phase 1 | 2026-03-31 | 2025-12-01 | −120 days |
| 2026-10-27 | ALN-CIDEB | NCT07631637Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 2 | 2029-02-06 | 2029-01-29 | −8 days |
| 2026-10-26 | Durvalumab | NCT04607954Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer | Phase 2 | 2026-09-01 | 2026-03-02 | −183 days |
| 2026-10-26 | Pembrolizumab | NCT06302426Trial of INI-4001 in Patients With Advanced Solid Tumours | Phase 1 | 2026-10-30 | 2026-06-19 | −133 days |
| 2026-10-26 | Pembrolizumab | NCT05382325A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | Phase 1 | 2026-09-30 | 2026-09-29 | −1 day |
| 2026-10-25 | Decitabine/cedazuridine (Inqovi) | NCT06091267PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes | Phase 1/2 | 2026-05-31 | 2026-05-22 | −9 days |
| 2026-10-24 | VY7523 | NCT06874621VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease | Phase 1/2 | 2027-05 | 2026-10-13 | −200 days |
| 2026-10-24 | QiShenYiQi | NCT06006689Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) | Phase 2 | 2025-09-01 | 2025-04-16 | −138 days |
| 2026-10-24 | Aficamten | NCT07023341A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 3 | 2026-08-31 | 2026-07-14 | −48 days |
| 2026-10-24 | pemetrexed | NCT04129502TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Phase 3 | 2026-10-31 | 2026-09-22 | −39 days |
| 2026-10-24 | Inavolisib | NCT07144111A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | Phase 1 | 2026-11-16 | 2026-10-13 | −34 days |
| 2026-10-24 | Cabotegravir/rilpivirine (Cabenuva) | NCT06468995Antiviral Long Acting Drugs Landing in People Living With HIV | Phase na | 2026-07-01 | 2026-06-19 | −12 days |
| 2026-10-24 | Iparomlimab and tuvonralimab, Bevacizumab | NCT07416058PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC | Phase 2 | 2027-12-31 | 2027-12-30 | −1 day |
| 2026-10-24 | Sonrotoclax | NCT07628881A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults | Phase 1 | 2026-09-27 | 2026-09-26 | −1 day |
| 2026-10-23 | Gemcitabine | NCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | Phase 2/3 | 2029-01-15 | 2027-12-01 | −411 days |
| 2026-10-23 | Sunvozertinib | NCT06295432A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) | Phase 2 | 2026-12 | 2026-06-08 | −176 days |
| 2026-10-23 | Docetaxel | NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Phase 3 | 2027-01-04 | 2026-10-19 | −77 days |
| 2026-10-23 | Dexamethasone, Lenalidomide, Bortezomib, Daratumumab | NCT03591744Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia | Phase 1 | 2019-10-25 | 2019-09-19 | −36 days |
| 2026-10-22 | Dexamethasone, CT-P44, Lenalidomide, Daratumumab | NCT06952478A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | Phase 3 | 2027-11-15 | 2027-03-08 | −252 days |
| 2026-10-22 | Pembrolizumab | NCT02977468Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer | Phase 1 | 2024-12-31 | 2024-07-18 | −166 days |
| 2026-10-22 | Letrozole, Denosumab (Prolia) | NCT06706414NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia | Phase 1/2 | 2026-08 | 2026-04-30 | −93 days |
| 2026-10-22 | Cabozantinib | NCT04412629Cabozantinib in High Grade Neuroendocrine Neoplasms | Phase 2 | 2026-09-30 | 2026-07-27 | −65 days |
| 2026-10-22 | budesonide MMX (Uceris), Budesonide | NCT05915104Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis | Phase 2 | 2026-09-01 | 2026-07-27 | −36 days |
| 2026-10-22 | Ribociclib, Trametinib, Cetuximab | NCT05358249Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1/2 | 2026-09-30 | 2026-09-28 | −2 days |
| 2026-10-21 | GDC-6988 | NCT06603246A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease | Phase 1 | 2027-11-15 | 2026-08-18 | −454 days |
| 2026-10-21 | Debecarasib, Cetuximab, Gemcitabine, Nab-paclitaxel | NCT06586515MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | 2029-03 | 2028-03 | −365 days |
| 2026-10-21 | Docetaxel, ONO-4578, Ramucirumab, Nivolumab | NCT06542731An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer | Phase 1 | 2026-09-12 | 2025-10-30 | −317 days |
| 2026-10-21 | Tovorafenib | NCT07206849Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) | Phase 2 | 2030-11 | 2030-02 | −273 days |
| 2026-10-21 | SHR-1918 | NCT07349615A Study of SHR-1918 In Participants With Hypertriglyceridemia | Phase 3 | 2027-11 | 2027-03 | −245 days |
| 2026-10-21 | Pembrolizumab | NCT06551064Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients | Phase 1 | 2026-06-30 | 2025-12-05 | −207 days |
| 2026-10-21 | tulisokibart | NCT07486960Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) | Phase 2 | 2027-08-13 | 2027-02-17 | −177 days |
| 2026-10-21 | Mivelsiran | NCT05231785A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD | Phase 1 | 2029-04-20 | 2029-01-11 | −99 days |
| 2026-10-21 | Tamoxifen (Soltamox) | NCT06361940Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | Phase 2 | 2028-12 | 2028-09 | −91 days |
| 2026-10-21 | Balcinrenone, Dapagliflozin | NCT07754331Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin | Phase 1 | 2026-12-03 | 2026-10-06 | −58 days |
| 2026-10-21 | Dexamethasone, Isatuximab, Lenalidomide | NCT05690984Elimination of Minimal Residual Disease After Transplant | Phase 2 | 2026-09 | 2026-08-19 | −13 days |
| 2026-10-21 | BG-68501, Fulvestrant, BGB-43395 | NCT06257264A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Phase 1 | 2026-08-31 | 2026-08-27 | −4 days |
| 2026-10-20 | Tenofovir alafenamide/emtricitabine, Darunavir | NCT06337032A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments | Phase 4 | 2034-03 | 2027-06 | −2465 days |
| 2026-10-20 | Nivolumab | NCT03854032Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | Phase 2 | 2025-12-31 | 2022-02-10 | −1420 days |
| 2026-10-20 | Methotrexate | NCT05600426A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) | Phase 3 | 2029-12 | 2026-08-06 | −1213 days |
| 2026-10-20 | WTX-330 | NCT06939283A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma | Phase 1/2 | 2028-08 | 2026-04-23 | −831 days |
| 2026-10-20 | Risvutatug rezetecan, Dostarlimab | NCT05277051First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Phase 1 | 2027-08-31 | 2026-06-30 | −427 days |
| 2026-10-20 | Aflibercept | NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | Phase 3 | 2028-11 | 2027-11 | −366 days |
| 2026-10-20 | Ipilimumab, Nivolumab | NCT06365619Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma | Phase 2 | 2027-08 | 2026-10 | −304 days |
| 2026-10-20 | dupilumab | NCT06116526Dupilumab De-escalation in Pediatric Atopic Dermatitis | Phase 4 | 2027-04-01 | 2026-07-18 | −257 days |
| 2026-10-20 | pemetrexed, Pembrolizumab | NCT04736173Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | Phase 2 | 2027-05 | 2026-09-17 | −226 days |
| 2026-10-20 | Olanzapine (Zyprexa), Insulin Lispro | NCT03741478Intranasal Insulin and Olanzapine Study in Healthy Volunteers | Phase 1 | 2026-07-30 | 2026-06-01 | −59 days |
| 2026-10-20 | BGM0504 | NCT07166081Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects | Phase 1 | 2026-05-13 | 2026-03-16 | −58 days |
| 2026-10-17 | Azacitidine, Venetoclax | NCT04062266AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | Phase 2 | 2030-10-31 | 2026-10-12 | −1480 days |
Showing the newest 300 of 784 moves. Each drug page lists every registry date for its own studies.
Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.